Invivoscribe Submits LeukoStrat® CDx FLT3 Mutation Assay to NMPA in China and Expands Company, Adding Laboratory in Shanghai to Provide Comprehensive Support for Partners.

2021-02-26T19:10:05-08:00May 12th, 2020|2020 Press Releases, Press Releases|